GenVec Announces Interim Survival Data In Pivotal Trial Of TNFerade™ In Locally Advanced Pancreatic Cancer

 20.11.2008 12:22   medicalnewstoday.com

GenVec, Inc. (Nasdaq:GNVC) announced today top-line results of an interim analysis from its ongoing Phase III Pancreatic Cancer Clinical Trial with TNFerade™ (PACT) in patients with locally advanced pancreatic cancer. This interim analysis of overall survival, conducted after the 92nd death (one-third of total expected events), was designed to determine whether the study should continue and took place in the time frame originally estimated.

World Urology